glp 1 agonist statpearls GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes A Closer Look at the
Description
10.1136/gut.46.5.622 108 SchirraJ.NicolausM.RoggelR.KatschinskiM.StorrM.WoerleH

This is especially important in the context of obesity treatment, where inappropriate prescribing practices have been a concern

2016;310(10):R88595

Eli Lilly is evaluating its lead asset, tirzepatide , in phase III obesity drug clinical trials for the reduction of morbidity and mortality in obesity

Leipold G, Tth R, Hrsfalvi P, Lczi L, Trk M, Keszthelyi A, et al

Old ways of doing business may soon stop working, but there are also new opportunities to adapt
